The Application of Emodin Treatment on Nasopharyngeal Carcinoma Therapy

Biomedicines. 2024 Feb 21;12(3):486. doi: 10.3390/biomedicines12030486.

Abstract

Nasopharyngeal carcinoma (NPC) is a malignancy prevailing in Taiwan, Hong Kong, Southern China, Southeast Asia, and North Africa. Although early-stage NPC responds well to the primary treatment of radio-chemotherapy, the mortality rate of advanced NPC remains high. Therefore, developing new therapies for nasopharyngeal carcinoma is an urgent task. Emodin is an anthraquinone derivative mainly found in Rheum palmatum. Emodin has been found to possess many anti-cancer functions against various types of cancers, but they are less discussed in the treatment of NPC. This review organized the different studies about the anti-NPC activity of emodin and discussed the potential and challenges of emodin treatment in NPC therapy.

Keywords: EBV; NPC therapy; emodin; nasopharyngeal carcinoma; natural compound.

Publication types

  • Review